Exploration of the DPP-4 inhibitors with a focus on saxagliptin

Bibliography

• World Diabetes Foundation. Available from: http://www.worlddiabetesfoundation.org/composite-35.htm [Last accessed 31 January 2009]
   Google Scholar
• National Diabetes Information Clearinghouse. Available from: http://diabetes.niddk.nih.gov/dm/pubs/statistics/#allages [Last accessed 31 January 2009]
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, Ten year follow up of intensive glucose control for type 2 diabetes mellitus. N Engl J Med 2008;359;15:1577-89
   PubMed Web of Science ®Google Scholar
• Ohkubo Y, Kishikawa H, Raki E, Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6 year study. Diabetes Res Clin Pract 1995;28:103-17
   PubMed Web of Science ®Google Scholar
• The ADVANCE Collaborative Group. Intensive blood glucose control and vascularoutcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;1:1-11
   Google Scholar
• Grant R, Buse JB, Meigs JB, Quality of diabetes care in US academic medical centers: low rates of medical regimen change. Diabetes Care 2005;28;2:337-42
   PubMed Web of Science ®Google Scholar
• Shah BR, Hux JE, Laupacis A. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care 2005;28:600-6
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control Diabetes Fact Sheet. Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf [Last accessed 31 January 2009]
   Google Scholar
• American Diabetes Association. Costs of Diabetes Care. Available from: http://www.diabetes.org/diabetes-statistics/cost-of-diabetes-in-us.jsp [Last accessed 31 January 2009]
   Google Scholar
• Alexander GC, Schgal NL, Moloney RM. National trends in the treatment of type 2 diabetes: 1994 – 2007. Arch Int Med 2008;169:2088-94
   Google Scholar
• Nathan DM, Buse JB, Davidson MB. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32;1:193-203
   PubMed Web of Science ®Google Scholar
• AACE Diabetes Mellitus Clinical Practice Guideline Task Force. American Association of Clinical Endocrinologists Medical Guidelines for Management of Diabetes Mellitus. Endocr Pract 2007;13(Suppl 1):3-68
   Google Scholar
• Bolen S, Feldman L, Vassy J. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Int Med 2007;147:386-99
   PubMed Web of Science ®Google Scholar
• Green B, Flatt P, Bailey C. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res 2006;159-65
   PubMedGoogle Scholar
• Sebokova E, Christ A, Boehringer M, Dipeptidyl peptidase IV inhibitors: the next generation of new promising therapies for the management of type 2 diabetes. Curr Top Med Chem 2006;7:547-55
   Web of Science ®Google Scholar
• Ahn JH, Shin MS, Jun MA, Synthesis, biological evaluation and structural determination of beta-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors. Bioorg Med Chem Lett 2007;17:2622-8
   PubMed Web of Science ®Google Scholar
• Kuhn B, Hennig M, Mattei P. Molecular recognition of ligands in dipeptidyl peptidase IV. Curr Top Med Chem 2007;7:609-19
   PubMed Web of Science ®Google Scholar
• Peters JU. 11 years of cyanopyrrolidines as DPP-IV inhibitors. Curr Top Med Chem 2007;7:579-95
   PubMed Web of Science ®Google Scholar
• Veken PV, Haemers A, Augustyns K. Prolyl peptidase related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery. Curr Top Med Chem 2007;7:621-35
   PubMed Web of Science ®Google Scholar
• Ferraris D, Belyakov S, Li W, Azetidine-based inhibitors of dipeptidyl peptidase IV (DPP IV). Curr Top Med Chem 2007;7:597-608
   PubMed Web of Science ®Google Scholar
• Onglyza (saxagliptin) package insert. August 2009. Bristol-Myers Squibb/AstraZeneca
   Google Scholar
• Cochrane database: Available from: http://mrw.interscience.wiley.com/cochrane_clcentral_articles_fs.html [Last accessed 31 January 2009]
   Google Scholar
• Clinical trials.gov. Available from: http://clinicaltrials.gov/ct2/results?term=saxagliptin [Last accessed 31 January 2009]
   Google Scholar
• Holst JJ. Glucagon-like peptide 1(GLP-1): an intestinal hormone signaling nutritional abundance, with unusual therapeutic potential. Trends Endocrinol Metab 1999;10:229-35
   PubMed Web of Science ®Google Scholar
• Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 2005;48:616-20
   PubMed Web of Science ®Google Scholar
• Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes. Systematic review and meta-analysis. JAMA 2007;298:194-206
   PubMed Web of Science ®Google Scholar
• VanDeKoppel S, Choe HM, Sweet BV. Managed care perspective on three new agents for type 2 diabetes. J Manag Care Pharm 2008;14:363-80
   PubMed Web of Science ®Google Scholar
• Wani JH, John-Kalarickal J, Fonseca VA. Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review. Cardiol Clin 2008;26:639-48
   PubMed Web of Science ®Google Scholar
• Miller SA, St Onge EL, Taylor JR. DPP-IV inhibitors: a review of sitagliptin, vildagliptin, alogliptin, and saxagliptin. Formulary 2008;43:122-34
   Google Scholar
• Jadinsky M, Pfutzner A, Paz-Pacheco E, ; for CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009;11:611-22
   PubMed Web of Science ®Google Scholar
• Augeri DJ, Robl JA, Betebenner DA, Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long acting, orally active dipeptidyl pepitdase IV inhibitor of type 2 diabetes. J Med Chem 2005;48:5025-37
   PubMed Web of Science ®Google Scholar
• Metzler WJ, Yanchunas J, Weigelt C, Involvement of DPP-IV catalytic residues in enzyme saxagliptin complex formation. Protein Sci 2008;17:240-50
   PubMed Web of Science ®Google Scholar
• Zhao G, Taunk PC, Magnin DR, Diprolyl nitriles as potent dipeptidyl pepitase IV inhibitors. Bioorg Med Chem Lett 2005;15:3992-5
   PubMed Web of Science ®Google Scholar
• Defronzo RA, Hissa M, Barber A, The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649-55
   PubMed Web of Science ®Google Scholar
• Boulton DW, Geraldes M. Safety, tolerability, pharmacokinetics of a once-daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects [abstract 606-P]. Presented at the 67th American Diabetes Association Scientific Sessions 2007 Orlando FL, USA
   Google Scholar
• Patel CG, Li L, Komoroski BJ, No effect of saxagliptin on QTc interval in healthy subjects. American Diabetes Association Scientific Sessions 2009, New Orleans, LA
   Google Scholar
• Rosenstock J, Aguilar-Salinas C, Klein E, Effect of saxagliptin montherapy in treatment naïve patients with type 2 diabetes. Curr Med Res Opin 2009;25:2401-11
   PubMed Web of Science ®Google Scholar
• DeFronzo R, Hissa MN, Garber AJ, Once-daily saxaglipitin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with type 2 diabetes mellitus. Abstract presented at the 69th Scientific Sessions of the American Diabetes Association 2009
   Google Scholar
• Hollander P, Li J, Allen E, Chen R; for the CV181-013 Investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009, in press
   Google Scholar
• Chen R, Dononvan M, Rusnak JM. Saxagliptin used as monotherapy or in combination with other antihyperglycemic agents does not significantly increase risk of hypoglycemia. Abstract presented at the 69th Scientific Sessions of the American Diabetes Association, 2009
   Google Scholar
• Boulton DW, Li L, Patel CG, No pharmacokinetic interaction between saxagliptin and digoxin in healthy subject. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting; 2-5 Apr 2008 Orlando, FL, USA. Clin Pharmacol Ther 2008;83:S93
   Google Scholar
• Boulton DW, Goyal A, Li L, The effects of age and gender on the single-dose pharmacokinetics and safety of saxagliptin in healthy subjects. Presented at 68th Scientific Sessions of the American Diabetes Association 2008;57 (S1):A164
   Google Scholar
• Boulton DW, Tang A, Patel CG, The influence of renal impairment on the pharmacokinetics of saxagliptin. Presented at American Society for Clinical Pharmacology and Therapeutics Annual Meeting; 18-21 Mar 2009, National Harbour MD, USA. Clin Pharmacol Ther 2009;85:S96
   Google Scholar
• Rosenstock J, Sankoh S, List JF, Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008;10:376-86
   PubMed Web of Science ®Google Scholar
• Patel CG, Wolf RA, Komoroski B, No meaningful pharmacokinetic drug–drug interactions between saxagliptin and pioglitazone in healthy subjects [abstract 226]. Presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting; 14-17 Oct 2007, Denver, CO, USA
   Google Scholar
• Patel CG, Li L, Komoroski B, No meaningful pharmacokinetic drug–drug interactions between saxagliptin and glyburide in healthy subjects [abstract 212]. Presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting; 14-17 Oct 2007, Denver, CO, USA
   Google Scholar
• Patel CG, Komoroski B, Brenner E, No meaningful pharmacokinetic drug–drug interactions between saxagliptin and metformin in healthy subjects [abstract 213]. Presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting; 14-17 Oct 2007, Denver, CO, USA.
   Google Scholar
• Patel C, Castaneda L, Frevert U, Single dose pharmacokinetics and safety of saxagliptin in subjects with hepatic impairment compared with healthy subjects [abstract 537-P]. Presented at 68th Scientific Sessions of the American Diabetes Association 2008
   Google Scholar
• Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug –naïve patients with type 2 diabetes. Diabetes Obes Metab 2008;10:376-86
   PubMed Web of Science ®Google Scholar
• Pratley RE. The new science of GLP-1: effects beyond glucose control. Johns Hopkins Adv Stud Med 2008;8;393-9
   Google Scholar
• Leiter LA. Beta-cell preservation: a potential role for thiazolidinedione to improve clinical care in type 2 diabetes. Diabet Med 2005;22:963-72
   PubMed Web of Science ®Google Scholar
• Viberti G, Lachin J, Holman R, A diabetes outcome progression trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabet Med 2006;23:1289-94
   PubMed Web of Science ®Google Scholar
• Xiang AH, Peters RK, Kjos SL, Effects of pioglitazone on pancreatic B-cell function and diabetes risk in hispanic women with prior gestational diabetes. Diabetes 2006;55:517-22
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Gomis R, Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7
   PubMed Web of Science ®Google Scholar
• Wani J, John-Kalarickal J, Fonseca V. Dipeptidal peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review. Cardiol Clin 2008;26:639-48
   PubMed Web of Science ®Google Scholar
• Gallwitz B. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data. Int J Clin Pract 2006;60:1654-61
   PubMed Web of Science ®Google Scholar
• Brubaker PL, Drucker DJ. Mini review: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004;145:2653-9
   PubMed Web of Science ®Google Scholar